ArticleACS nano2025
Reprogramming Immunodeficiency in Lung Metastases via PD-L1 siRNA Delivery and Antigen Capture of Nanosponge-Mediated Dendritic Cell Modulation.
Article in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- A Self-assembly Carrier-Free Nanovaccine based on Fluorinated CpG and Neoantigen Peptides for Hepatocellular Carcinoma Immunotherapy.International journal of pharmaceutics: X · 2026Article
- Opportunities and challenges for cancer immunotherapy based on antigen cross-presentation.Annals of medicine · 2026Review
- Lyophilized bacteria-infected tumor cells for targeted immunotherapy of lung metastases and associated fibrosis.Bioactive materials · 2026Article
- Nonsurgical Platelet Membrane-Decorated Gold Yarnball Brain Antenna for In Situ Nitric Oxide Generation and Neuronal Regeneration.ACS nano · 2026Article
- Nano-hydrogel-based delivery system for dihydroartemisinin to enhance cuproptosis and synergize with anti-PD-1 therapy in triple-negative breast cancer.Journal of nanobiotechnology · 2026Article
- Environment-Responsive Sustained-Release Nanoparticles for the Protection, Delivery and Release of Clove Essential Oil to Improve Foodborne Bacterial Colitis Treatment.Advanced healthcare materials · 2026Article
- Cross-species hybrid vesicles enable synergistic immunochemotherapy through enhanced targeted drug delivery and immune activation.Journal of nanobiotechnology · 2026Article
- ZnJournal of nanobiotechnology · 2026Article
- In silico design of CLDN4-directed peptide-loaded nanobubbles for ultrasound-assisted delivery, photothermal therapy, immune activation, and multimodal imaging in ovarian cancer.Journal of nanobiotechnology · 2026Article
- Dual metabolic intervention nanoplatform co-delivering BAY-876 and L-cystine for Wilms tumor therapy via disulfidptosis-associated cytoskeletal collapse.Journal of nanobiotechnology · 2026Article
- Article
- Hybrid membrane-camouflaged photothermal immunomodulatory nanoparticle inhibits colorectal cancer growth and metastasis.International journal of pharmaceutics: X · 2026Article
- Hypoxia-relieving and glycolysis-disrupting polydopamine nanomedicine for synergistic chemo-photothermal therapy of hepatocellular carcinoma.International journal of pharmaceutics: X · 2026Article
- Article
- Heat shock protein 60-targeted peptide-conjugated platinum nanozyme: redox regulation by multi-enzyme activities induces mitochondrial reprogramming and acute leukemia cells fate switch.Journal of nanobiotechnology · 2026Article
- Folic acid-modified antigen-trapping nanoprobes for developing in situ tumor vaccines to inhibit metastasis and recurrence of ovarian cancer.Journal of nanobiotechnology · 2026Article
- MXene-based CRISPR/Cas9 nanoplatform targeting FABP5 for ROS amplification and synergistic photothermal/photodynamic therapy of cervical cancer.Journal of nanobiotechnology · 2026Article
- The interplay between autophagy and immunogenic cell death: nanomaterial-based strategies for cancer immunotherapy.Journal of nanobiotechnology · 2026Review
- Enhanced mRNA vaccine combined with immune checkpoint blockade efficiently suppresses tumor growth and metastasis.Journal of nanobiotechnology · 2026Article
- Brain-targeting nanoplatform repurposing silymarin for enhanced GBM immunotherapy via synergistic mitochondrial suppression.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infiltration of cytotoxic T lymphocytes into hypovascular metastases offers significant potential for suppressing even the most intractable metastatic tumors, with dendritic cells (DCs) serving as pivotal initiators of antitumor immune responses during immunotherapy. However, the immune-privileged nature of hypovascular lung metastases combined with the inherently low immunogenicity of tumor clusters poses substantial barriers to effective lymphocyte recruitment. Here, a pH-responsive lung metastatic-targeted catalyst containing the tumor penetration polymer (TP)/solid lipids (SL)-coated Prussian blue (TP-SL@PB)-enhanced PD-L1 siRNA delivery and self-cascade antigen capture is developed for reprogramming immunodeficiency. Intravenously injected TP-SL@PB accumulated in the blood vessel-poor lung metastases via the organ-selective targeting and charge conversion of TP. In tumor clusters, SL@PB exerts catalytic and lysosomal escape effects, easily enhancing siRNA delivery and thus downregulating PD-L1. Catalysis also promotes the release of tumor-associated antigens (TAAs), including neoantigens and damage-associated molecular patterns. Subsequently, both positive TPs and SLs on PBs can act as antigen sponges to deliver TAAs to dendritic cells, thereby inducing long-term immune activation. TP-SL@PB acts as a hypovascularized lung metastasis-penetrating catalytic nanosponge, selecting T cells to infiltrate metastases and enhance immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.